Ewing Sarcoma - Pipeline Review, H2 2017

  • ID: 4433853
  • Report
  • 326 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Ipsen SA
  • Merck & Co Inc
  • MORE
Ewing Sarcoma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Ipsen SA
  • Merck & Co Inc
  • MORE
Introduction

Ewing Sarcoma - Overview

Ewing Sarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Ewing Sarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ewing Sarcoma - Companies Involved in Therapeutics Development

Amgen Inc

AntiCancer Inc

Astellas Pharma Inc

Bristol-Myers Squibb Co

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

Eisai Co Ltd

EntreChem SL

Exelixis Inc

Gradalis Inc

Incyte Corp

Ipsen SA

MacroGenics Inc

MediaPharma SRL

Merck & Co Inc

Merrimack Pharmaceuticals Inc

NantKwest Inc

Novartis AG

Oncomatryx Biopharma SL

Oncternal Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Tarveda Therapeutics Inc

Tesaro Inc

Ewing Sarcoma - Drug Profiles

12-B80 - Drug Profile

aldoxorubicin hydrochloride - Drug Profile

axitinib - Drug Profile

Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile

cabozantinib s-malate - Drug Profile

CEB-01 - Drug Profile

Cellular Immunotherapy 2 for Oncology - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Celyvir - Drug Profile

Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile

EC-8042 - Drug Profile

EC-8105 - Drug Profile

enoblituzumab - Drug Profile

everolimus - Drug Profile

ganitumab - Drug Profile

gemogenovatucel-T - Drug Profile

INCB-59872 - Drug Profile

ipilimumab + nivolumab - Drug Profile

irinotecan hydrochloride - Drug Profile

istiratumab - Drug Profile

JS-K - Drug Profile

KITSG-3227 - Drug Profile

KTN-0182A - Drug Profile

lenvatinib mesylate - Drug Profile

linsitinib - Drug Profile

lurbinectedin - Drug Profile

Monoclonal Antibody Conjugates for Ewing Sarcoma - Drug Profile

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile

MPTEM-1ADC - Drug Profile

niraparib - Drug Profile

NV-101 - Drug Profile

NV-103 - Drug Profile

OMTX-503 - Drug Profile

OMTX-703 - Drug Profile

ONC-206 - Drug Profile

ONCase-PEG - Drug Profile

paclitaxel albumin bound - Drug Profile

pazopanib hydrochloride - Drug Profile

pembrolizumab - Drug Profile

PEN-866 - Drug Profile

RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile

sirolimus albumin-bound - Drug Profile

Small Molecules for Ewing Sarcoma - Drug Profile

SP-2509 - Drug Profile

SP-2577 - Drug Profile

talazoparib - Drug Profile

TK-216 - Drug Profile

Ewing Sarcoma - Dormant Projects

Ewing Sarcoma - Discontinued Products

Ewing Sarcoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Ewing Sarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ewing Sarcoma - Pipeline by Amgen Inc, H2 2017

Ewing Sarcoma - Pipeline by AntiCancer Inc, H2 2017

Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H2 2017

Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2017

Ewing Sarcoma - Pipeline by Cebiotex SL, H2 2017

Ewing Sarcoma - Pipeline by Celgene Corp, H2 2017

Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017

Ewing Sarcoma - Pipeline by Eisai Co Ltd, H2 2017

Ewing Sarcoma - Pipeline by EntreChem SL, H2 2017

Ewing Sarcoma - Pipeline by Exelixis Inc, H2 2017

Ewing Sarcoma - Pipeline by Gradalis Inc, H2 2017

Ewing Sarcoma - Pipeline by Incyte Corp, H2 2017

Ewing Sarcoma - Pipeline by Ipsen SA, H2 2017

Ewing Sarcoma - Pipeline by MacroGenics Inc, H2 2017

Ewing Sarcoma - Pipeline by MediaPharma SRL, H2 2017

Ewing Sarcoma - Pipeline by Merck & Co Inc, H2 2017

Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Ewing Sarcoma - Pipeline by NantKwest Inc, H2 2017

Ewing Sarcoma - Pipeline by Novartis AG, H2 2017

Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H2 2017

Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H2 2017

Ewing Sarcoma - Pipeline by Pfizer Inc, H2 2017

Ewing Sarcoma - Pipeline by Pharma Mar SA, H2 2017

Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2017

Ewing Sarcoma - Pipeline by Tesaro Inc, H2 2017

Ewing Sarcoma - Dormant Projects, H2 2017

Ewing Sarcoma - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Ewing Sarcoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • AntiCancer Inc
  • Astellas Pharma Inc
  • Bristol-Myers Squibb Co
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Eisai Co Ltd
  • EntreChem SL
  • Exelixis Inc
  • Gradalis Inc
  • Incyte Corp
  • Ipsen SA
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Merrimack Pharmaceuticals Inc
  • NantKwest Inc
  • Novartis AG
  • Oncomatryx Biopharma SL
  • Oncternal Therapeutics Inc
  • Pfizer Inc
  • Pharma Mar SA
  • Tarveda Therapeutics Inc
  • Tesaro Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll